Calgary, AB, Canada Clinical Trials

A listing of Calgary, AB, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 137 clinical trials
featured
C2541013 MIRNA NASH  

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement …

University of Calgary
 (3.0 away)
  • 275 views
  • 30 Jul, 2021
  • +64 other locations
featured
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada  

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.   This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept …

epoetin alfa
Tom Baker Cancer Centre
 (2.9 away)
  • 33 views
  • 03 Aug, 2021
  • +9 other locations
A Safety Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects will be discontinued once they experience sJIA …

Alberta Children's Hospital, University of Calgary
 (5.6 away) Contact site
  • 134 views
  • 02 Aug, 2021
  • +100 other locations
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Tom Baker Cancer Centre
 (2.9 away) Contact site
  • 2496 views
  • 24 Jul, 2021
  • +209 other locations
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Galderma Investigational Site 8085
 (0.6 away) Contact site
  • 21 views
  • 04 Aug, 2021
  • +474 other locations
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is compared to apremilast in adult participants with moderate plaque psoriasis. Adverse events and change in disease symptoms will be monitored. …

arthritis
plaque psoriasis
risankizumab
apremilast
systemic therapy
Beacon Dermatology Inc /ID# 230121
 (2.8 away) Contact site
  • 0 views
  • 04 Aug, 2021
  • +61 other locations
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate …

progressive disease
testosterone
prostate adenocarcinoma
androgen
androgen suppression
Research Site
 (4.2 away) Contact site
  • 200 views
  • 23 Jul, 2021
  • +194 other locations
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy. All …

remission
cardiomyopathy
cyclophosphamide
corticosteroid therapy
granulomatosis
Research Site
 (3.0 away) Contact site
  • 21 views
  • 03 Aug, 2021
  • +80 other locations
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have …

transitional cell carcinoma
pembrolizumab
carboplatin
gemcitabine
metastatic urothelial carcinoma
Site CA11004
 (2.9 away) Contact site
  • 5 views
  • 21 Jul, 2021
  • +111 other locations
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).

Galderma Investigational Site
 (4.6 away) Contact site
  • 0 views
  • 30 Jul, 2021
  • +140 other locations